Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100


Early clinical trials of Toca 511 and Toca FC show a promising novel treatment for recurrent malignant glioma.

Philbrick BD, Adamson DC.

Expert Opin Investig Drugs. 2019 Mar;28(3):207-216. doi: 10.1080/13543784.2019.1572112. Review.


Toca 511 gene transfer and 5-fluorocytosine in combination with temozolomide demonstrates synergistic therapeutic efficacy in a temozolomide-sensitive glioblastoma model.

Huang TT, Hlavaty J, Ostertag D, Espinoza FL, Martin B, Petznek H, Rodriguez-Aguirre M, Ibañez CE, Kasahara N, Gunzburg W, Gruber HE, Pertschuk D, Jolly DJ, Robbins JM.

Cancer Gene Ther. 2013 Oct;20(10):544-51. doi: 10.1038/cgt.2013.51. Epub 2013 Aug 23.


Toca 511 plus 5-fluorocytosine in combination with lomustine shows chemotoxic and immunotherapeutic activity with no additive toxicity in rodent glioblastoma models.

Yagiz K, Huang TT, Lopez Espinoza F, Mendoza D, Ibañez CE, Gruber HE, Jolly DJ, Robbins JM.

Neuro Oncol. 2016 Oct;18(10):1390-401. doi: 10.1093/neuonc/now089. Epub 2016 May 10.


Intravenous administration of retroviral replicating vector, Toca 511, demonstrates therapeutic efficacy in orthotopic immune-competent mouse glioma model.

Huang TT, Parab S, Burnett R, Diago O, Ostertag D, Hofman FM, Espinoza FL, Martin B, Ibañez CE, Kasahara N, Gruber HE, Pertschuk D, Jolly DJ, Robbins JM.

Hum Gene Ther. 2015 Feb;26(2):82-93. doi: 10.1089/hum.2014.100. Epub 2015 Jan 19.


Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC.

Cloughesy TF, Landolfi J, Vogelbaum MA, Ostertag D, Elder JB, Bloomfield S, Carter B, Chen CC, Kalkanis SN, Kesari S, Lai A, Lee IY, Liau LM, Mikkelsen T, Nghiemphu P, Piccioni D, Accomando W, Diago OR, Hogan DJ, Gammon D, Kasahara N, Kheoh T, Jolly DJ, Gruber HE, Das A, Walbert T.

Neuro Oncol. 2018 Sep 3;20(10):1383-1392. doi: 10.1093/neuonc/noy075.


Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma model.

Mitchell LA, Lopez Espinoza F, Mendoza D, Kato Y, Inagaki A, Hiraoka K, Kasahara N, Gruber HE, Jolly DJ, Robbins JM.

Neuro Oncol. 2017 Jul 1;19(7):930-939. doi: 10.1093/neuonc/nox037.


Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma.

Cloughesy TF, Landolfi J, Hogan DJ, Bloomfield S, Carter B, Chen CC, Elder JB, Kalkanis SN, Kesari S, Lai A, Lee IY, Liau LM, Mikkelsen T, Nghiemphu PL, Piccioni D, Walbert T, Chu A, Das A, Diago OR, Gammon D, Gruber HE, Hanna M, Jolly DJ, Kasahara N, McCarthy D, Mitchell L, Ostertag D, Robbins JM, Rodriguez-Aguirre M, Vogelbaum MA.

Sci Transl Med. 2016 Jun 1;8(341):341ra75. doi: 10.1126/scitranslmed.aad9784.


Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.

Ostertag D, Amundson KK, Lopez Espinoza F, Martin B, Buckley T, Galvão da Silva AP, Lin AH, Valenta DT, Perez OD, Ibañez CE, Chen CI, Pettersson PL, Burnett R, Daublebsky V, Hlavaty J, Gunzburg W, Kasahara N, Gruber HE, Jolly DJ, Robbins JM.

Neuro Oncol. 2012 Feb;14(2):145-59. doi: 10.1093/neuonc/nor199. Epub 2011 Nov 9.


Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas.

Newlands ES, Foster T, Zaknoen S.

Br J Cancer. 2003 Jul 21;89(2):248-51.


A Retroviral Replicating Vector Encoding Cytosine Deaminase and 5-FC Induces Immune Memory in Metastatic Colorectal Cancer Models.

Yagiz K, Rodriguez-Aguirre ME, Lopez Espinoza F, Montellano TT, Mendoza D, Mitchell LA, Ibanez CE, Kasahara N, Gruber HE, Jolly DJ, Robbins JM.

Mol Ther Oncolytics. 2017 Dec 5;8:14-26. doi: 10.1016/j.omto.2017.12.001. eCollection 2018 Mar 30.


Combination chemotherapy using carboplatin (JM-8) and etoposide (JET therapy) for recurrent malignant gliomas: a phase II study.

Watanabe K, Kanaya H, Fujiyama Y, Kim P.

Acta Neurochir (Wien). 2002 Dec;144(12):1265-70; discussion 1270.


Procarbazine, lomustine and vincristine for recurrent high-grade glioma.

Parasramka S, Talari G, Rosenfeld M, Guo J, Villano JL.

Cochrane Database Syst Rev. 2017 Jul 26;7:CD011773. doi: 10.1002/14651858.CD011773.pub2. Review.


Multimodality management of recurrent adult malignant gliomas: results of a phase II multiagent chemotherapy study and analysis of cytoreductive surgery.

Rostomily RC, Spence AM, Duong D, McCormick K, Bland M, Berger MS.

Neurosurgery. 1994 Sep;35(3):378-88; discussion 388.


Temozolomide with radiation therapy in high grade brain gliomas: pharmaceuticals considerations and efficacy; a review article.

Koukourakis GV, Kouloulias V, Zacharias G, Papadimitriou C, Pantelakos P, Maravelis G, Fotineas A, Beli I, Chaldeopoulos D, Kouvaris J.

Molecules. 2009 Apr 16;14(4):1561-77. doi: 10.3390/molecules14041561. Review.


Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials.

Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, Levin VA, Yung WK.

J Clin Oncol. 1999 Aug;17(8):2572-8.


A phase II study of carboplatin and chronic high-dose tamoxifen in patients with recurrent malignant glioma.

Tang P, Roldan G, Brasher PM, Fulton D, Roa W, Murtha A, Cairncross JG, Forsyth PA.

J Neurooncol. 2006 Jul;78(3):311-6. Epub 2006 May 19.


Nitrosourea efficacy in high-grade glioma: a survival gain analysis summarizing 504 cohorts with 24193 patients.

Wolff JE, Berrak S, Koontz Webb SE, Zhang M.

J Neurooncol. 2008 May;88(1):57-63. doi: 10.1007/s11060-008-9533-5. Epub 2008 Feb 6.


Chemotherapy for high-grade gliomas.

Galanis E, Buckner J.

Br J Cancer. 2000 Apr;82(8):1371-80. Review. No abstract available.


Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas.

Holdhoff M, Ye X, Supko JG, Nabors LB, Desai AS, Walbert T, Lesser GJ, Read WL, Lieberman FS, Lodge MA, Leal J, Fisher JD, Desideri S, Grossman SA, Wahl RL, Schiff D.

Neuro Oncol. 2017 Jun 1;19(6):845-852. doi: 10.1093/neuonc/nox020.


Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.

Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, Kesari S, Wen PY.

Neurology. 2008 Mar 4;70(10):779-87. doi: 10.1212/01.wnl.0000304121.57857.38.


Supplemental Content

Support Center